THEIR FUTURE STARTS WITH YOU

HeartMate 3™ LVAD with Full MagLev™ Flow Technology

FEATURING
THE FULL-COHORT ANALYSIS OF THE MOMENTUM 3 TRIAL
HEARTMATE 3™ LVAD DELIVERS UNPRECEDENTED* SURVIVAL AND SAFETY OUTCOMES**¹

MOMENTUM 3 was the largest left ventricular assist device (LVAD) trial ever conducted.*** The results at 2 years show that the HeartMate 3™ LVAD continues to have:

THE HIGHEST SURVIVAL RATE FOR ANY LVAD IN A RANDOMIZED CONTROLLED TRIAL†,¹-³

THE LOWEST HEMOCOMPATIBILITY-RELATED ADVERSE EVENT RATES OF ANY LVAD††,¹-⁴

IMMEDIATE, SIGNIFICANT AND SUSTAINED IMPROVEMENTS IN FUNCTIONAL CAPACITY AND QUALITY OF LIFE¹

Based on published data from multicenter experience and separate studies, which may involve different patient populations and other variables. Not a head-to-head comparison. Data presented for informational purposes only.

See Important Safety Information referenced within.
LANDMARK SURVIVAL WITH HEARTMATE 3™ LVAD
Approaching that of heart transplant survival at 2 years†††

OVERALL SURVIVAL BY THERAPEUTIC INTENT

THE GOAL OF THERAPY IS TO IMPROVE SURVIVAL AND QUALITY OF LIFE WHILE REDUCING COMPLICATIONS, REGARDLESS OF PRE-IMPLANT STRATEGY.®

BTC = Bridge to Candidacy. BTT = Bridge to Transplant. DT = Destination Therapy. See Important Safety Information referenced within.
THE LOWEST HEMOCOMPATIBILITY-RELATED ADVERSE EVENT (HRAE) RATES FOR ANY LVAD†††1-4

HRAE refers to the constellation of bleeding, stroke and thrombosis events that often aggregate together in the same individual.

<table>
<thead>
<tr>
<th>MOBILEM 3 2019¹</th>
<th>ENDURANCE 2017²</th>
</tr>
</thead>
<tbody>
<tr>
<td>HeartMate III LVAD (n = 516)</td>
<td>HeartMate II LVAD (n = 512)</td>
</tr>
<tr>
<td>9.9% / 0.08 (% / EPPY)</td>
<td>19.4% / 0.18 (% / EPPY)</td>
</tr>
<tr>
<td>10%</td>
<td>1%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MOBILEM 3 2019¹</th>
<th>ENDURANCE 2017²</th>
</tr>
</thead>
<tbody>
<tr>
<td>HeartMate III LVAD (n = 516)</td>
<td>HeartMate II LVAD (n = 148)</td>
</tr>
<tr>
<td>1.0%</td>
<td>11.1%</td>
</tr>
<tr>
<td>1%</td>
<td>10.7%</td>
</tr>
</tbody>
</table>

EPPY = Events per patient-year.

HRAE includes bleeding > 30 days, stroke, pump thrombosis, arterial thromboembolism, non-stroke neurological event (inconclusive or hematologic in etiology).

Based on published data from multicenter experience and separate studies, which may involve different patient populations and other variables. Not a head-to-head comparison. Data presented for informational purposes only.

At 2 years nearly half of HeartMate 3 LVAD patients did not experience a bleeding event.⁴
OUTCOMES MADE POSSIBLE BY FULL MAGLEV™ FLOW TECHNOLOGY

Full MagLev™ Flow Technology maintains gentle blood handling to minimize complications and reduce HRAEs.

- **FULLY LEVITATED, SELF-CENTERING ROTOR** that does not require hydrodynamic or mechanical bearings
- **LARGE, CONSISTENT BLOOD FLOW PATHWAYS** to reduce shear stress\(^9\)
- **INTRINSIC PULSATILITY** (30 cycles per minute) to reduce blood stasis and minimize thrombus\(^9,10\)

See Important Safety Information referenced within.
MAKING A MEANINGFUL DIFFERENCE IN PATIENTS’ LIVES

Immediate, significant and sustained improvements in functional capacity and quality of life

79% of patients improved from NYHA Class III/IV at baseline to NYHA Class I/II by 6 months, with sustained improvement of 80% of patients through 2 years (P < 0.0001).1,12

Quality of life score improved significantly and was sustained at 2 years.1

KCCQ = Kansas City Cardiomyopathy Questionnaire.

Significant increase in 6-minute walk distance1

136 m (approx. 149 yards) at baseline (n = 471)
323 m (approx. 353 yards) at 24 months (n = 211)

Note: One football field = 91 m (100 yards).

Significantly lower hospital readmission rate and fewer readmission days compared to HeartMate II™ LVAD12

<table>
<thead>
<tr>
<th>INDEX HOSPITALIZATION</th>
<th>HEARTMATE 3™ LVAD (n = 515)</th>
<th>HEARTMATE II™ LVAD (n = 505)</th>
<th>P VALUE4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Length of stay for implant hospitalization (median days) (Q1, Q3)</td>
<td>19 (14, 25)</td>
<td>17 (14, 24)</td>
<td>0.11</td>
</tr>
<tr>
<td>Days on LVAD support outside of hospital (median) (Q1, Q3)</td>
<td>653 (333, 696)</td>
<td>605 (259, 690)</td>
<td>0.008</td>
</tr>
<tr>
<td>Readmission days in the hospital (median) (Q1, Q3)</td>
<td>13 (4, 37)</td>
<td>18 (6, 40)</td>
<td>0.02</td>
</tr>
<tr>
<td>Readmissions due to any cause (EPPY)</td>
<td>2.26</td>
<td>2.47</td>
<td>0.03</td>
</tr>
</tbody>
</table>

See Important Safety Information referenced within.
HEARTMATE 3™ LVAD SYSTEM

A better experience for clinicians and patients

HeartMate 3™ LVAD
Connected to the left side of the heart and moves oxygenated blood from the left ventricle to the rest of the body

Batteries
Provide up to 17 hours of uninterrupted power

Modular driveline
Facilitates simple replacement of externalized portion

Pocket controller
Powers and controls the LVAD and is small enough to fit in a pocket. Includes emergency backup battery

Mobile Power Unit (MPU)
Plug-in power source

See Important Safety Information referenced within.
By choosing the HeartMate 3™ LVAD, you can go above and beyond to make a meaningful difference in your patients’ lives.

THEIR FUTURE STARTS WITH YOU

EMPOWERING THE TRANSFORMATION OF HEART FAILURE

From treatment to ongoing patient management, Abbott is committed to working with you to transform heart failure and improve more patient lives.

---

3. Markham DW. Two-year Outcomes in the ENDURANCE Supplemental Trial. American Heart Association (AHA) Annual Meeting; November 10, 2018; Chicago, IL.
4. Uriel N. Long-Term Burden of Hemocompatibility Related Adverse Events in the MOMENTUM 3 Trial: Final Analysis of the 1028 Patient Cohort. The International Society for Heart & Lung Transplantation (ISHLT) Annual Meeting. April 4, 2019; Orlando, FL.
8. Goldstein DJ. Clinical Outcomes by Intended Goal of Therapy in the MOMENTUM 3 Clinical Trial: Analysis of the Full Cohort. The International Society for Heart & Lung Transplantation (ISHLT) Annual Meeting. April 4, 2019; Orlando, FL.

Abbott
One St. Jude Medical Dr., St. Paul, MN 55117 USA, Tel: 1 651 756 2000
HeartMate3.com
Rx Only

Important Safety Information

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

Indications: The HeartMate 3™ Left Ventricular Assist System is indicated for providing short-and long-term mechanical circulatory support (e.g., as bridge to transplant or myocardial recovery, or destination therapy) in patients with advanced refractory left ventricular heart failure.

Contraindications: The HeartMate 3 Left Ventricular Assist System is contraindicated for patients who cannot tolerate, or who are allergic to, anticoagulation therapy.

Adverse Events: Adverse events that may be associated with the use of the HeartMate 3 Left Ventricular Assist System are: death, bleeding, cardiac arrhythmia, localized infection, right heart failure, respiratory failure, device malfunctions, driveline infection, renal dysfunction, sepsis, stroke, other neurological event (not stroke-related), hepatic dysfunction, psychiatric episode, venous thromboembolism, hypertension, arterial non-central nervous system (CNS) thromboembolism, pericardial fluid collection, pump pocket or pseudo pocket infection, myocardial infarction, wound dehiscence, hemolysis (not associated with suspected device thrombosis) or device thrombosis.

™ Indicates a trademark of the Abbott group of companies.
† Indicates a third party trademark, which is property of its respective owner.
© 2019 Abbott. All Rights Reserved.

SJM-0517-00009(3) | Item approved for U.S. use only.